Bosh sahifaDRREDDY • NSE
Dr Reddy's Laboratories Ltd
1 214,00 ₹
22-noy, 15:58:28 (GMT+5:30) · INR · NSE · Ogohlantirish
AksiyalarIN qimmatli qogʻoziBosh shtabi: IN
Yopilish kursi
1 195,35 ₹
Kunlik diapazon
1 193,60 ₹ - 1 223,20 ₹
Yillik diapazon
1 074,00 ₹ - 1 421,49 ₹
Bozor kapitalizatsiyasi
1,01 trln INR
Oʻrtacha hajm
1,48 mln
Narx/foyda
18,96
Dividend daromadliligi
0,66%
Asosiy maydon
NSE
CDP reytingi
A-
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(INR)sen, 2024Y/Y qiyosi
Daromad
80,16 mlrd16,51%
Joriy xarajat
29,72 mlrd24,54%
Sof foyda
12,55 mlrd-15,18%
Sof foyda marjasi
15,66-27,20%
Har bir ulushga tushum
15,83-11,13%
EBITDA
22,02 mlrd8,53%
Amaldagi soliq stavkasi
30,01%
Jami aktivlari
Jami passivlari
(INR)sen, 2024Y/Y qiyosi
Naqd pul va qisqa investitsiyalar
63,07 mlrd-7,15%
Jami aktivlari
465,96 mlrd34,27%
Jami passivlari
156,67 mlrd66,79%
Umumiy kapital
309,28 mlrd
Tarqatilgan aksiyalar
833,05 mln
Narxi/balansdagi bahosi
3,26
Aktivlardan daromad
10,24%
Kapitaldan daromad
13,21%
Naqd pulning sof oʻzgarishi
(INR)sen, 2024Y/Y qiyosi
Sof foyda
12,55 mlrd-15,18%
Operatsiyalardan naqd pul
9,32 mlrd-48,03%
Sarmoyadan naqd pul
-19,07 mlrd-322,21%
Moliyadan naqd pul
16,15 mlrd329,53%
Naqd pulning sof oʻzgarishi
6,37 mlrd1,03%
Boʻsh pul
3,92 mlrd-72,47%
Haqida
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
Tashkil etilgan
1984
Xodimlar soni
27 048
Yana
Bu sizni qiziqtirishi mumkin
Bu roʻyxat oxirgi qidiruvlar, kuzatilgan aksiyalar va boshqa faoliyatdan tuzilgan. Batafsil

Barcha axborotlar faqat maʼlumot sifatida “shundayligicha” taqdim etilgan, ulardan moliyaviy maslahat sifatida foydalanmang, ular savdo maqsadlari yoki investitsiya, soliq, yuridik, buxgalteriya yoki boshqa turdagi maslahat emas. Google investitsiya borasida maslahatchi emas, bu roʻyxatdagi kompaniyalar yoki ularning aksiyalari borasida hech qanday nuqtai nazar, tavsiya yoki fikr bildirmaydi. Har qanday savdoni boshlashdan oldin broker yoki moliyaviy vakil bilan maslahatlashib, narxlarni tekshiring. Batafsil
Aloqador qidiruvlar
Qidiruv
Qidiruv maydonini tozalash
Qidiruvni yopish
Google ilovalari
Asosiy menyu